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ABSTRACT 
Background Freezing of gait in Parkinson’s disease can be difficult to study in the laboratory.  
Here we investigate the use of a variable-width doorway to provoke freeze behaviour together 
with new objective methods to measure it. With this approach we compare the effects of anti-
parkinsonian treatments (medications and deep-brain stimulation of the subthalamic nucleus) on 
freezing and other gait impairments. 
Methods Ten ‘freezers’ and 10 control participants were studied. Whole-body kinematics were 
measured while participants walked at preferred speed in each of four doorway conditions (no 
door present, door width at 100, 125 and 150 % shoulder width) and in four treatment states 
(offmeds/offstim, offmeds/onstim, onmeds/offstim, onmeds/onstim). 
Results With no doorway, the Parkinson’s group showed characteristic gait disturbances 
including slow speed, short steps and variable step timing. Treatments improved these 
disturbances. The Parkinson’s group slowed further at doorways by an amount inversely 
proportional to door width, suggesting a visuomotor dysfunction. This was not improved by 
either treatment alone. Finally, Freeze-like events were successfully provoked near the doorway 
and their prevalence significantly increased in narrower doorways. These were defined clinically 
and by two objective criteria which correlated well with clinical ratings. The risk of Freeze-like 
events was reduced by medication but not by deep-brain stimulation. 
Conclusions Freeze behaviour can be provoked in a replicable experimental setting using the 
variable-width doorway paradigm, and measured objectively using two definitions introduced 
here. The differential effects of medication and deep-brain stimulation on the gait disturbances 
highlight the complexity of Parkinsonian gait disorders and their management. 
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INTRODUCTION 
Parkinson’s disease (PD) can cause ‘freezing’ episodes where the feet become involuntarily 
‘stuck to the ground’. This phenomenon has proved difficult to study in the laboratory, meaning 
that its pathophysiological basis and treatment remain poorly understood. Here we describe a 
new approach for provoking and measuring freezes in a controlled setting. The work addresses 
three important challenges in studying freeze behaviour.  
First, how can we evoke freezes in laboratory settings? Here we exploit the fact that 
freezing episodes occur in tight spaces or doorways for around half of PD patients who freeze 
[1]. Recent studies have built on this observation by showing that in laboratory settings ‘freezers’ 
(PD patients susceptible to freezing episodes) slow down excessively as they approach a 
doorway [2,3]. In the present study our first aim was to evoke freezing using this previously 
developed variable-width doorway paradigm [2], where the doorway is scaled to each 
individual’s shoulder width. This approach complements work using sudden obstacle appearance 
[4], surface translation [5], or slowing [6], to provoke freeze behaviour in a simple, naturalistic 
and replicable manner. 
Second, how should we measure freezes? Traditionally, freezing is a clinically-defined 
phenomenon that reflects the patient’s subjective impression that their feet are ‘glued to the 
floor’. Sometimes a freeze event is obvious to an observer, but it becomes increasingly difficult 
to be certain if episodes are short and the external signs of the patient’s internal struggle to move 
are not apparent. Here we follow a recent trend [4,7] and develop two separate objective 
measures of freezing to complement clinical definitions and allow better comparison of data 
collected in different laboratories under diverse conditions. 
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Third, can we use these approaches to assess current treatments of freezing? To 
investigate this we measure doorway-provoked freeze behaviour in a group of patients treated 
with medications and deep-brain stimulation of the subthalamic nucleus (STN-DBS). While 
STN-DBS improves clinical [8,9] and kinematic [10-13] aspects of gait, there is mixed evidence 
on whether it reduces the number of freezing episodes [14,15]. Here we establish whether the 
variable-width doorway paradigm provides a suitable method for assessing the risk of freezing 
under different treatment states. The resulting data must be considered specific to our particular 
patient sample and surgical group; nevertheless they further our understanding both of how to 
study and how to treat freezing of gait in PD. 
 
METHODS 
Research was approved by the joint ethics committee of the National Hospital for Neurology and 
Neurosurgery (NHNN) and UCL Institute of Neurology, London, UK. Written informed consent 
was obtained before testing. 
Participants 
Ten patients with idiopathic PD (8 males, mean age 59.8yrs, s.d. 7.3yrs), and ten matched 
healthy controls, (HC: 8 males, mean age 62.8yrs, s.d. 5.8yrs) took part. Patients were recruited 
from the NHNN and classified by a movement disorders neurologist as presenting with freezing 
of gait. They had no serious cognitive impairments, assessed by a neurologist, or uncorrected 
visual impairments. The mean duration of PD was 14.6 years (sd 4yrs). All had been implanted 
with bilateral STN electrodes using an MRI-guided technique [16,17]. Stimulators had been 
fitted on average 4.02 years prior to testing (sd 2.5 yrs) and the response had stabilised. 
Treatments are shown in Table 1. 
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PD participants visited the laboratory twice within a month. On each occasion, they were 
first tested ‘off medication’ (> 12 hours withholding medication). One hour after taking their 
normal morning dose, tests were repeated ‘on medication’. On the first visit tests were performed 
with the stimulator turned on, and on the second visit >15 minutes after the stimulator had been 
turned off. This allowed efficient data collection, especially off medication.  
Apparatus 
Kinematic data were obtained using a CODA motion-capture system (Charnwood Dynamics, 
Rothley, UK), with markers placed bilaterally on the lateral malleolus, 2nd metatarsal head, 
posterior aspect of calcaneus at height of toe marker, anterior superior iliac spine (ASIS) and 
sacrum.  Two vertical planks of wood, each 15cm wide formed a doorway extending from the 
ground to a pelmet at 210cm. Door width was adjusted using a motor.  
Design & Procedure 
Walking task: Participants walked a 6.32m straight path. A set of trials started with a walk in one 
direction followed by one in the opposite direction, repeated to give four trials per set providing 
the patient was able. Each block started with a set of no-door trials, followed by three sets of 
door trials, where door width was scaled to 150, 125, or 100% of the participant’s shoulder width 
(left to right acromion). Door width order was randomised between participants. PD participants 
completed one block in each treatment state. They were instructed to pass through the doorway 
naturally. Perceptual task: Perception, including perception of door width, can be altered in PD 
[18,19]. To assess this we had participants judge the width of doorway they could just pass 
through, as described in [2]. Turn task: Axial turns can be a potent trigger of freezing [20]. Since 
participants may turn slightly in the approach to a doorway, we wanted to check if this 
movement contributed to the freezing we observed in doorways.  We therefore had participants 
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6
complete a short turning task consisting of two tight 360° turns clockwise and two anticlockwise 
in each testing block. Clinical measures: The cardinal motor features of PD were assessed with 
the Unified Parkinson’s Disease Rating Scale Part III (UPDRS; [21]). Freezing at home was 
assessed using the FOG Questionnaire (FOG-Q;[22]). 
Analysis 
Gait variables: Position data were low-pass filtered in both directions at 10 Hz with a 2nd order 
Butterworth filter. Toe-off and heel-strike were selected by a custom Matlab (MathWorks Inc, 
Natick, MA, USA) routine and visually confirmed by a single trained observer. Stride time was 
the time between successive foot-strikes of the same foot. Stride time variability was measured 
by the coefficient of variation of stride times, considered across both feet. Stride length was the 
distance travelled by the heel in the transverse plane during a stride. On each trial we calculated 
the mean value of these freeze-related gait variables [3,23, 24] in a 2.8m region surrounding the 
door (as in [2]), and averaged across trials of the same type to give mean values for each door 
and treatment condition.  
Freezes and freeze-like events: We report three separate measures of freeze behaviour. 
Clinical ratings were made from video by an experienced neurologist (PL), blind to treatment 
condition. Each of our two objective definitions of ‘freeze-like events’ (FLEs) is based on the 
assumption that freezes are rare, episodic events which should be considered relative to each 
participant’s baseline walking performance. In the first definition (Fig 1A), a FLE is an 
unusually long period of double support for that person. For each participant in each treatment 
condition we calculated a distribution of double support times, and defined an unusually high 
double support time as being more than 3.1 standard deviations above the mean for that 
condition. In the second, separate definition (Fig 1B), a FLE is an extremely slow period of 
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walking for that person. For each participant in each treatment condition, we calculated baseline 
velocity across the middle 3.32m of the walkway on no-door trials, and defined a FLE as a 
period in which velocity dropped below 10% of baseline. These criteria were set to be stringent 
but also capable of detecting shorter freezes. For further details and validation, see 
Supplementary materials. 
Statistical analysis: Two repeated measures ANOVAs were conducted on each gait 
parameter. The first assessed the factors of door width, stimulation and medication in PD 
participants; the second, group differences with factors door width and group (HC vs PD 
participants in off/off state). For freezing, we report the number of trials on which one or more 
freezes or FLEs occurred and the total time spent in FLE’s; and use multiple logistic regression 
analysis [25] to quantify how the risk of a FLE depended on door width and treatment. This 
describes the relationship between predictor variables (e.g. medication state) and a dichotomous 
outcome variable (FLE or non-FLE trial). The first stage of this analysis is to calculate, in each 
treatment or door width condition, the odds : p (FLE trial) / p (non-FLE trial). The odds ratio 
then compares odds in different conditions (e.g. on vs off medication). Importantly, odds ratios 
significantly lower than one indicate that the risk of a FLE is significantly different between 
conditions. For each FLE definition a single logistic regression analysis was conducted which 
measured the independent effects of medication, stimulation and door width on FLE risk, with 
statistics adjusted for the presence of multiple variables. To assess perceptual judgements in PD 
participants we used an ANOVA with factors medication and stimulation; to compare the HC 
group with the PD group off/off we used a second ANOVA. Because of unequal variances, non-
parametric Mann-Whitney U and Friedman tests were used to compare turn time across groups 
and treatment states respectively. 
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8
 
RESULTS 
Clinical measures 
The mean score on the FOG-Q was 10.2 (sd 3.8), indicating moderately severe freezing. Mean 
UPDRS part III motor scores were: off stim/off meds, 39.4 (sd 9.7); off stim/on meds, 30.6 (sd 
12.7); on stim/off    meds, 22.2 (sd 10.1), on stim/onmeds, 14.1 (sd 8.2). Scores were lower with 
stimulation alone than with medication alone, perhaps because medication dosages were not as 
high as pre-operative levels, or because the effects of medication alone are reduced after chronic 
stimulation [26]. 
Gait variables 
Walking velocity dropped as the body approached the door (Fig 2), with larger drops for 
narrower doors. Analyses of gait parameters (Tables 2 & 3) showed that in the PD group, door 
width significantly affected all variables. Medication improved the mean levels of all variables 
(i.e. increased velocity and stride length, and decreased stride time variability), but changed the 
scaling to door width only of stride time variability. Stimulation improved the mean levels only 
of velocity and stride length, and did not change scaling to door width of any variable. 
Significant group by door width effects for all variables indicated that PD participants and 
healthy controls scaled their responses to door width differently. When compared to the HC 
group, PD participants had amplified responses, such that the same reduction in door width led to 
greater drops in velocity and stride length, and a greater rise in stride time variability. 
Freeze behaviour 
On clinical ratings and both separate FLE definitions, freeze or FLE frequency increased as door 
width narrowed (Fig 3A), and was reduced by medication but not stimulation (Fig 3A,B). 
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9
Statistical analyses showed that for both FLE definitions, FLE risk was significantly reduced by 
medication (p<0.001) but not stimulation (Fig 3D). Comparing FLE risk on medium and narrow 
door conditions with a wide door baseline condition showed that risk significantly increased as 
doors became narrower (Fig 3C). After controlling for the effects of medication, medium doors 
doubled or trebled FLE risk, and narrow doors increased the risk approximately tenfold 
compared with the wide-door trials (p <0.001). We could not perform statistical analyses on 
duration data because of the uneven spread of FLEs across conditions. However, the longest 
FLEs occurred at the narrowest door width (Supplementary materials) and in the untreated 
condition; the trend was for both treatments to decrease FLE duration (Supplementary materials). 
Perceptual and motor performance 
Because of fatigue, one participant did not complete the perceptual task and one did not complete 
the turning task. Explicit judgements of door width by PD participants (Fig 4A) were not 
affected by medication (F(1,8)=.53, p=.487) or stimulation (F(1,8)=2.920, p=.126), with no 
interaction (F(1,8)=1.931, p=.202). These judgements were not different between HC and PD 
groups (t(17)=-0.079, p=.938).  
The time to turn 360° was significantly different betwe n HCs and untreated PD 
participants (Mann-Whitney U = 2.0, p<0.001; Fig 4B), and significantly affected by treatment 
state (χ2(3)=13.41, p=.004). However, turn time in the PD group did not significantly correlate 
with the extent of slowing experienced in doors (velocity drop from no-door to narrow door 
condition in off/off state) (p=.167, p=.668). Thus neither perceptual performance nor turning 
ability could account for slowing and freezing in doorways. 
 
DISCUSSION 
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10
We used a variable-width doorway paradigm and two quantitative freeze-like event (FLE) 
definitions to provoke and measure freezing in a replicable manner. We then compared the 
effects of medications and STN-DBS on walking and freezing within the same, naturalistic 
setting.  
Slow walking and its treatment 
Patients exhibited characteristic parkinsonian gait disturbances of short steps and low 
velocity [23].  As in other studies, both medication and STN-DBS improved these symptoms 
[13,24]. Doorways produced striking additional effects on PD gait. Narrower doors caused 
shorter strides in healthy controls, but consistent with previous studies [2,3] this effect was 
greatly amplified in the PD group. We assume that these gait disturbances are specific to PD 
freezers since a previous study [3] found clear differences in the slowing phenomenon between 
the FOG and non-FOG groups. Slowing at doorways did not likely result from changes in the 
background stride lengths of the groups, since medications and STN-DBS significantly increased 
this but did not improve the slowing effect of doors (there were no door-width by treatment 
interactions). Rather, the observed slowing may result from a visuomotor process, where visually 
specified information about door width determines how much one must slow down to pass 
through the door accurately. The dramatic slowing of PD freezers is consistent with the 
hypothesis that visuomotor processing is different in these patients, specifically that they produce 
exaggerated responses to visual information [2]. This perspective may help explain the 
exaggerated responses of PD patients in other tasks [27-30]. An alternative explanation is that 
the doorway removes attention from walking, thus interfering with voluntary compensation for 
an underlying short stride length [31]. Neither medication nor STN-DBS alleviated door width-
related slowing. This is of course specific to our patient sample and should be tested across 
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11
different patient and surgical groups; however, the failure of medications to change door width-
related slowing replicates an earlier study with a different, non-implanted group [2]. Together 
these studies suggest that brain regions other than the basal ganglia may play a role in door-
provoked slowing. Interestingly, lateral premotor areas of cortex in PD patients have been 
reported to show excessive activation to visual information during walking [32] and may process 
visual information for walking as they do for reaching [33-35]. 
Freeze behaviour and its treatment 
We used two criteria to define objectively freeze-like events (FLEs). These agreed well with 
clinical ratings of freeze behaviour and provide objective measures comparable to inter-rater 
reliability (Supplementary material). Future studies should validate these measures in a larger 
cohort of patients. However, considering the data in this way removed the subjective element 
from defining freeze events, and provided measures which allow reliable, replicable 
identification of freezes, even those of short duration. These measures showed that freeze 
behaviour tends to occur near a doorway and with greater frequency as door width decreases. 
This confirms the observation that doorways elicit freeze behaviour in PD [1] and shows that the 
doorway is a powerful tool for experimentally manipulating fr ezing in a simple, naturalistic and 
replicable manner. Doorway-evoked freezing can be used as an important complement to other 
recently described methods of evoking freezes in laboratory settings [4, 5, 6], and future work 
may wish to compare these methods experimentally. 
A particularly influential theory of freezing is that it is caused by a reduction in baseline 
stridelength coupled to a sequence effect (progressive shortening of steps during walking) [6]. As 
discussed above our data are partially consistent with the relation between slowing and freezing 
– here we found that both were sensitive to door width. Indeed the slowing produced by 
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12
visuomotor dysfunction could in turn cause freezing through a sequence effect [6,36,37]. Indeed, 
closing eyes can help reduce freezing [38]. However, the differential effects of the two 
treatments suggest that other mechanisms may have contributed to freezing in the current study. 
That is, both treatments significantly improved baseline walking speed and door-width related 
slowing, whereas only medication reduced the risk of freezing (STN-DBS did not). The results 
are consistent with the suggestion that high stride time variability is associated with freezing [39] 
because, like freezing, it was improved by medication but not by STN-DBS. This discussion of 
how gait variables relate t  freezing is based on the variation we naturally observed across 
different treatment conditions. In future work it would be ideal to also experimentally manipulate 
gait variables, for example by asking patients or healthy controls to walk at a different stride 
length. 
The lack of a STN-DBS effect on freezing is especially notable for several reasons. First, 
STN-DBS increased walking speed and stride length. Second, in the same session, UPDRS 
scores were improved more by STN-DBS than by medication. Third, the postoperative drug 
doses were less than would have been given if the disease had progressed without surgery, yet, in 
contrast to STN-DBS, medication still reduced FLE risk . Consistent with previous work [15], 
the relative weakness of STN-DBS as a therapeutic tool is therefore quite specific to freezing. Of 
course, this need not generalise to all PD patients. The effects of STN on post-operative freezing 
are best predicted by the pre-operative response to levodopa [15] and stimulation parameters 
must be carefully adjusted [14]. While STN-DBS may effectively reduce freezing in some 
patients, the present study highlights its potential limitations and the need to continue exploring 
new treatments for this disabling symptom of PD. However, the assessment of treatments is not 
straightforward as freezing is a complex phenomenon with idiosyncratic properties [40]. Much 
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13
work is therefore needed to develop theories of freezing which can account for the pattern of 
behaviour in the wide range of situations where it occurs. 
Summary 
The variable-width doorway paradigm coupled with reproducible measurements of freeze 
behaviour provides a new experimental approach for investigating freezing. Using this approach, 
we show that the risk of freezing is highly sensitive to door width. The differential effects of 
treatments in this setting suggest separable mechanisms for the patients’ slow walking, door 
width-related slowing, and door width-related freezing, and highlight the need to explore 
alternative treatments for severe freezing of gait. 
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FIGURE LEGENDS 
 
Figure 1 Freeze-like event (FLE) definition shown for one example patient. FLEs defined as 
(A) outliers in distribution of double support times for each participant within each condition (B) 
times where velocity falls <10% of mean value on no-door trials. 
 
Figure 2 Walking velocity. Pelvis midpoint velocity in direction of progression, as a function of 
position in space. Traces f r single PD participant in off/off state. Data filtered at 1Hz, plotted 
for each door condition. Dashed lines show measurement region. 
 
Figure 3 Freezes. Total freeze / FLE trials observed per condition across all PD participants by 
(A) door (B) treatment condition. Effects of (C) door width (D) treatment condition on odds ratio 
(FLE risk). Mean and 95% confidence intervals shown. 
 
Figure 4 Perceptual and motor performance. Means and standard errors shown by group and 
treatment for (A) passability judgements (B) time to turn 360°. 
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Table 1. Treatments. 
  
Participant Stimulation parameters    Medications 
 Amplitude (V) Frequency (Hz) Pulse width (µs) Type 
Daily dose 
(mg) 
 L R L R L R   
1 4.1 2.85 145 145 60 60 Ropinirole 24 
       Amantadine 300 
         
2 3 3.1 150 150 60 60 Sinemet 1000 
       Cabergoline 2 
         
3 3.6 2.8 145 130 60 60 Sinemet 600 
       Amantadine 100 
       Entacapone 200 
       Rasagiline 1 
         
4 4 3 180 180 60 60 Sinemet 900 
       Ropinirole 15 
       Amantadine 300 
         
5 3.6 3.6 145 145 90 60 Madopar 500 
       Sinemet 200 
       Ropinirole 20 
         
6 2 3.4 130 130 60 60 Madopar 300 
       Pramipexole 1.608 
         
7 3.5 4.3 185 185 60 90 Madopar 500 
       Ropinirole 15 
       Amantadine 200 
       Selegiline 5 
         
8 3.8 3.2 130 130 60 90 Sinemet 150 
       Ropinirole 12 
       Amantadine 200 
         
9 3.8 3.5 130 130 60 60 Madopar 500 
       Entacapone 600 
         
10 3.7 3.8 130 130 60 60 Madopar 500 
       Ropinirole 6 
       Amantadine 200 
 
Sinemet and Madopar expressed as mg levodopa. 
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Table 2.  Mean gait variables. 
 
 
Group means and standard errors for PD participants and healthy controls, at four door widths (no: no door; w: wide door; m: medium door; n: 
narrow door). Shown in four treatment states. 
 
 HC  PD 
   Off stim 
Off med 
 Off stim 
On med 
 On stim 
Off med 
 On stim 
On med 
                         
 
 no w m n  no w m n  no w m n  no w m n  no w m n 
                           
mean  1.09 1.15 1.14 1.08  .77 .71 .66 .53  .96 .84 .82 .72  .95 .94 .84 .75  1.10 1.09 1.04 0.98 Velocity 
(m/s) se  .03 .04 .04 .04  .12 .11 .09 .10  .09 .11 .09 .09  .07 .08 .08 .09  .08 .07 .08 .09 
                           
mean  1.23 1.24 1.23 1.18  .86 .76 .73 .54  1.07 .95 .90 .80  1.02 .97 .87 .79  1.19 1.12 1.06 1.00 Stride 
Length 
(m) se 
 .02 .03 .03 .03  .11 .11 .09 .09  .10 .12 .09 .09  .07 .07 .08 .08  .08 .08 .08 .10 
                           
mean  2.03 2.28 2.42 3.36  5.04 11.09 12.10 45.43  4.41 5.96 6.33 17.30  3.89 5.32 8.68 14.67  3.39 3.88 5.06 8.54 Stride 
time cv 
(%) Se 
 .19 .18 .22 .50  1.64 3.82 3.83 20.24  1.12 1.53 1.77 7.42  0.51 1.17 2.46 3.41  0.46 0.54 0.99 1.92 
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Table 3. Gait variable ANOVAs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two ANOVAs for each of three variables. (i) PD: effects of door width, stimulation and 
medication (ii) PD off /off vs healthy participants: effects of door width and group. p values 
(< .05) shown in bold. G: Greenhouse-Geisser corrected values. 
 
 
Velocity Stride length 
Stride time 
variability 
 
d.f. F p F p F p 
PD Group 
ANOVAs 
stim xmed x dr 
stim x meds 
meds x door 
stim x door 
stimulation 
medication 
door 
 
 
3,27 
1,9 
3,27 
3,27 
1,9 
1,9 
3,27 
 
 
0.33 
0.07 
1.90 
1.57 
23.53 
15.43 
36.85 
 
 
.807 
.796 
.153 
.219 
.001 
.003 
.000 
 
 
0.23 
0.33 
1.66 
1.85 
15.47 
11.67 
42.45 
 
 
.877 
.580 
.199 
.163 
.003 
.008 
.000 
 
 
2.18 
1.98 
5.87 
1.88 
2.05 
7.91 
6.93 
 
 
.114
G
 
.193 
.003
 G
 
.157
 G
 
.186 
.020 
.001
 G
 
PD offoff vs. 
HC ANOVAs 
door x group 
door 
group 
 
 
3,54 
3,54 
1,18 
 
 
9.39 
13.81 
18.22 
 
 
.000            
.000 
.000 
 
 
9.66 
20.44 
25.00 
 
 
.000 
.000 
.000 
 
 
3.83 
4.34 
5.14 
 
 
.015 
.050
 G
 
.036 
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Supplementary material: Freeze-like-event Definitions 
In order to validate our two objective measures of FOG, we compared each measure with clinical 
ratings using the Hansen-Kuiper or True Skill Score. This is a means of assessing how well one 
categorical predictor agrees with another, and takes into account both the hit rate and the false 
alarm rate of the predictor. In this case the dependent variable to be predicted is “FOG or non-FOG 
trial”. The score is given by 
POD – POFD 
Where POD = H/(H+M)  and  POFD = F/(Z+F) 
And H= hits; M = misses; F = false alarms; Z=correct rejections. 
 
Results may range between -1 for total disagreement and 1 for total agreement between rating 
systems. Using this score, we compared each measure not only with the clinical rater whose data are 
presented in the paper, but also with a second clinical rater (TF). TF was an experienced neurologist 
and was blind to the ratings made both by the objective definitions and the by first clinical rater. We 
compared each objective definition (DS, VelDef) to each clinical rater (PL, TF), giving four 
comparisons. As a standard of reliability we also compared the two clinical raters against each other. 
We therefore made a total of 5 comparisons. 
The results of these are shown below. Each of the 5 comparison types is shown in a separate column 
of points. Each point represents a comparison made for one participant. The grey horizontal bars 
indicate the mean score across all participants.  
 
Considering first the inter-rater reliability between the two clinical raters, it is apparent that 
agreement is around 0.5, but that there is a large spread of values around this point (ie agreement is 
higher for some subjects). Next considering the four columns to the right, we see that our two 
objective definitions agree with the clinical raters almost as well as the raters agree with each other. 
Comparing the definitions with the clinical inter-rater reliability in this way enables quantitative 
comparison of their validity and indicates that either of these definitions can be used as an objective 
means of identifying freezes that produces results comparable with inter-rater reliability. 
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2
ABSTRACT 
Background Freezing of gait in Parkinson’s disease can be difficult to study in the laboratory.  
Here we investigate the use of a variable-width doorway to provoke freeze behaviour together 
with new objective methods to measure it. With this approach we compare the effects of anti-
parkinsonian treatments (medications and deep-brain stimulation of the subthalamic nucleus) on 
freezing and other gait impairments. 
Methods Ten ‘freezers’ and 10 control participants were studied. Whole-body kinematics were 
measured while participants walked at preferred speed in each of four doorway conditions (no 
door present, door width at 100, 125 and 150 % shoulder width) and in four treatment states 
(offmeds/offstim, offmeds/onstim, onmeds/offstim, onmeds/onstim). 
Results With no doorway, the Parkinson’s group showed characteristic gait disturbances 
including slow speed, short steps and variable step timing. Treatments improved these 
disturbances. The Parkinson’s group slowed further at doorways by an amount inversely 
proportional to door width, suggesting a visuomotor dysfunction. This was not improved by 
either treatment alone. Finally, Freeze-like events were successfully provoked near the doorway 
and their prevalence significantly increased in narrower doorways. These were defined clinically 
and by two objective criteria which correlated well with clinical ratings. The risk of Freeze-like 
events was reduced by medication but not by deep-brain stimulation. 
Conclusions Freeze behaviour can be provoked in a replicable experimental setting using the 
variable-width doorway paradigm, and measured objectively using two definitions introduced 
here. The differential effects of medication and deep-brain stimulation on the gait disturbances 
highlight the complexity of Parkinsonian gait disorders and their management. 
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3
INTRODUCTION 
Parkinson’s disease (PD) can cause ‘freezing’ episodes where the feet become involuntarily 
‘stuck to the ground’. This phenomenon has proved difficult to study in the laboratory, meaning 
that its pathophysiological basis and treatment remain poorly understood. Here we describe a 
new approach for provoking and measuring freezes in a controlled setting. The work addresses 
three important challenges in studying freeze behaviour.  
First, how can we evoke freezes in laboratory settings? Here we exploit the fact that 
freezing episodes occur in tight spaces or doorways for around half of PD patients who freeze 
[1]. Recent studies have built on this observation by showing that in laboratory settings ‘freezers’ 
(PD patients susceptible to freezing episodes) slow down excessively as they approach a 
doorway [2,3]. In the present study our first aim was to evoke freezing using this previously 
developed variable-width doorway paradigm [2], where the doorway is scaled to each 
individual’s shoulder width. This approach complements work using sudden obstacle appearance 
[4], surface translation [5], or slowing [6], to provoke freeze behaviour in a simple, naturalistic 
and replicable manner. 
Second, how should we measure freezes? Traditionally, freezing is a clinically-defined 
phenomenon that reflects the patient’s subjective impression that their feet are ‘glued to the 
floor’. Sometimes a freeze event is obvious to an observer, but it becomes increasingly difficult 
to be certain if episodes are short and the external signs of the patient’s internal struggle to move 
are not apparent. Here we follow a recent trend [4,7] and develop two separate objective 
measures of freezing to complement clinical definitions and allow better comparison of data 
collected in different laboratories under diverse conditions. 
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4
Third, can we use these approaches to assess current treatments of freezing? To 
investigate this we measure doorway-provoked freeze behaviour in a group of patients treated 
with medications and deep-brain stimulation of the subthalamic nucleus (STN-DBS). While 
STN-DBS improves clinical [8,9] and kinematic [10-13] aspects of gait, there is mixed evidence 
on whether it reduces the number of freezing episodes [14,15]. Here we establish whether the 
variable-width doorway paradigm provides a suitable method for assessing the risk of freezing 
under different treatment states. The resulting data must be considered specific to our particular 
patient sample and surgical group; nevertheless they further our understanding both of how to 
study and how to treat freezing of gait in PD. 
 
METHODS 
Research was approved by the joint ethics committee of the National Hospital for Neurology and 
Neurosurgery (NHNN) and UCL Institute of Neurology, London, UK. Written informed consent 
was obtained before testing. 
Participants 
Ten patients with idiopathic PD (8 males, mean age 59.8yrs, s.d. 7.3yrs), and ten matched 
healthy controls, (HC: 8 males, mean age 62.8yrs, s.d. 5.8yrs) took part. Patients were recruited 
from the NHNN and classified by a movement disorders neurologist as presenting with freezing 
of gait. They had no serious cognitive impairments, assessed by a neurologist, or uncorrected 
visual impairments. The mean duration of PD was 14.6 years (sd 4yrs). All had been implanted 
with bilateral STN electrodes using an MRI-guided technique [16,17]. Stimulators had been 
fitted on average 4.02 years prior to testing (sd 2.5 yrs) and the response had stabilised. 
Treatments are shown in Table 1. 
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5
PD participants visited the laboratory twice within a month. On each occasion, they were 
first tested ‘off medication’ (> 12 hours withholding medication). One hour after taking their 
normal morning dose, tests were repeated ‘on medication’. On the first visit tests were performed 
with the stimulator turned on, and on the second visit >15 minutes after the stimulator had been 
turned off. This allowed efficient data collection, especially off medication.  
Apparatus 
Kinematic data were obtained using a CODA motion-capture system (Charnwood Dynamics, 
Rothley, UK), with markers placed bilaterally on the lateral malleolus, 2nd metatarsal head, 
posterior aspect of calcaneus at height of toe marker, anterior superior iliac spine (ASIS) and 
sacrum.  Two vertical planks of wood, each 15cm wide formed a doorway extending from the 
ground to a pelmet at 210cm. Door width was adjusted using a motor.  
Design & Procedure 
Walking task: Participants walked a 6.32m straight path. A set of trials started with a walk in one 
direction followed by one in the opposite direction, repeated to give four trials per set providing 
the patient was able. Each block started with a set of no-door trials, followed by three sets of 
door trials, where door width was scaled to 150, 125, or 100% of the participant’s shoulder width 
(left to right acromion). Door width order was randomised between participants. PD participants 
completed one block in each treatment state. They were instructed to pass through the doorway 
naturally. Perceptual task: Perception, including perception of door width, can be altered in PD 
[18,19]. To assess this we had participants judge the width of doorway they could just pass 
through, as described in [2]. Turn task: Axial turns can be a potent trigger of freezing [20]. Since 
participants may turn slightly in the approach to a doorway, we wanted to check if this 
movement contributed to the freezing we observed in doorways.  We therefore had participants 
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6
complete a short turning task consisting of two tight 360° turns clockwise and two anticlockwise 
in each testing block. Clinical measures: The cardinal motor features of PD were assessed with 
the Unified Parkinson’s Disease Rating Scale Part III (UPDRS; [21]). Freezing at home was 
assessed using the FOG Questionnaire (FOG-Q;[22]). 
Analysis 
Gait variables: Position data were low-pass filtered in both directions at 10 Hz with a 2nd order 
Butterworth filter. Toe-off and heel-strike were selected by a custom Matlab (MathWorks Inc, 
Natick, MA, USA) routine and visually confirmed by a single trained observer. Stride time was 
the time between successive foot-strikes of the same foot. Stride time variability was measured 
by the coefficient of variation of stride times, considered across both feet. Stride length was the 
distance travelled by the heel in the transverse plane during a stride. On each trial we calculated 
the mean value of these freeze-related gait variables [3,23, 24] in a 2.8m region surrounding the 
door (as in [2]), and averaged across trials of the same type to give mean values for each door 
and treatment condition.  
Freezes and freeze-like events: We report three separate measures of freeze behaviour. 
Clinical ratings were made from video by an experienced neurologist (PL), blind to treatment 
condition. Each of our two objective definitions of ‘freeze-like events’ (FLEs) is based on the 
assumption that freezes are rare, episodic events which should be considered relative to each 
participant’s baseline walking performance. In the first definition (Fig 1A), a FLE is an 
unusually long period of double support for that person. For each participant in each treatment 
condition we calculated a distribution of double support times, and defined an unusually high 
double support time as being more than 3.1 standard deviations above the mean for that 
condition. In the second, separate definition (Fig 1B), a FLE is an extremely slow period of 
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7
walking for that person. For each participant in each treatment condition, we calculated baseline 
velocity across the middle 3.32m of the walkway on no-door trials, and defined a FLE as a 
period in which velocity dropped below 10% of baseline. These criteria were set to be stringent 
but also capable of detecting shorter freezes. For further details and validation, see 
Supplementary materials. 
Statistical analysis: Two repeated measures ANOVAs were conducted on each gait 
parameter. The first assessed the factors of door width, stimulation and medication in PD 
participants; the second, group differences with factors door width and group (HC vs PD 
participants in off/off state). For freezing, we report the number of trials on which one or more 
freezes or FLEs occurred and the total time spent in FLE’s; and use multiple logistic regression 
analysis [25] to quantify how the risk of a FLE depended on door width and treatment. This 
describes the relationship between predictor variables (e.g. medication state) and a dichotomous 
outcome variable (FLE or non-FLE trial). The first stage of this analysis is to calculate, in each 
treatment or door width condition, the odds : p (FLE trial) / p (non-FLE trial). The odds ratio 
then compares odds in different conditions (e.g. on vs off medication). Importantly, odds ratios 
significantly lower than one indicate that the risk of a FLE is significantly different between 
conditions. For each FLE definition a single logistic regression analysis was conducted which 
measured the independent effects of medication, stimulation and door width on FLE risk, with 
statistics adjusted for the presence of multiple variables. To assess perceptual judgements in PD 
participants we used an ANOVA with factors medication and stimulation; to compare the HC 
group with the PD group off/off we used a second ANOVA. Because of unequal variances, non-
parametric Mann-Whitney U and Friedman tests were used to compare turn time across groups 
and treatment states respectively. 
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8
 
RESULTS 
Clinical measures 
The mean score on the FOG-Q was 10.2 (sd 3.8), indicating moderately severe freezing. Mean 
UPDRS part III motor scores were: off stim/off meds, 39.4 (sd 9.7); off stim/on meds, 30.6 (sd 
12.7); on stim/off    meds, 22.2 (sd 10.1), on stim/onmeds, 14.1 (sd 8.2). Scores were lower with 
stimulation alone than with medication alone, perhaps because medication dosages were not as 
high as pre-operative levels, or because the effects of medication alone are reduced after chronic 
stimulation [26]. 
Gait variables 
Walking velocity dropped as the body approached the door (Fig 2), with larger drops for 
narrower doors. Analyses of gait parameters (Tables 2 & 3) showed that in the PD group, door 
width significantly affected all variables. Medication improved the mean levels of all variables 
(i.e. increased velocity and stride length, and decreased stride time variability), but changed the 
scaling to door width only of stride time variability. Stimulation improved the mean levels only 
of velocity and stride length, and did not change scaling to door width of any variable. 
Significant group by door width effects for all variables indicated that PD participants and 
healthy controls scaled their responses to door width differently. When compared to the HC 
group, PD participants had amplified responses, such that the same reduction in door width led to 
greater drops in velocity and stride length, and a greater rise in stride time variability. 
Freeze behaviour 
On clinical ratings and both separate FLE definitions, freeze or FLE frequency increased as door 
width narrowed (Fig 3A), and was reduced by medication but not stimulation (Fig 3A,B). 
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9
Statistical analyses showed that for both FLE definitions, FLE risk was significantly reduced by 
medication (p<0.001) but not stimulation (Fig 3D). Comparing FLE risk on medium and narrow 
door conditions with a wide door baseline condition showed that risk significantly increased as 
doors became narrower (Fig 3C). After controlling for the effects of medication, medium doors 
doubled or trebled FLE risk, and narrow doors increased the risk approximately tenfold 
compared with the wide-door trials (p <0.001). We could not perform statistical analyses on 
duration data because of the uneven spread of FLEs across conditions. However, the longest 
FLEs occurred at the narrowest door width (Supplementary materials) and in the untreated 
condition; the trend was for both treatments to decrease FLE duration (Supplementary materials). 
Perceptual and motor performance 
Because of fatigue, one participant did not complete the perceptual task and one did not complete 
the turning task. Explicit judgements of door width by PD participants (Fig 4A) were not 
affected by medication (F(1,8)=.53, p=.487) or stimulation (F(1,8)=2.920, p=.126), with no 
interaction (F(1,8)=1.931, p=.202). These judgements were not different between HC and PD 
groups (t(17)=-0.079, p=.938).  
The time to turn 360° was significantly different between HCs and untreated PD 
participants (Mann-Whitney U = 2.0, p<0.001; Fig 4B), and significantly affected by treatment 
state (χ2(3)=13.41, p=.004). However, turn time in the PD group did not significantly correlate 
with the extent of slowing experienced in doors (velocity drop from no-door to narrow door 
condition in off/off state) (p=.167, p=.668). Thus neither perceptual performance nor turning 
ability could account for slowing and freezing in doorways. 
 
DISCUSSION 
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10
We used a variable-width doorway paradigm and two quantitative freeze-like event (FLE) 
definitions to provoke and measure freezing in a replicable manner. We then compared the 
effects of medications and STN-DBS on walking and freezing within the same, naturalistic 
setting.  
Slow walking and its treatment 
Patients exhibited characteristic parkinsonian gait disturbances of short steps and low 
velocity [23].  As in other studies, both medication and STN-DBS improved these symptoms 
[13,24]. Doorways produced striking additional effects on PD gait. Narrower doors caused 
shorter strides in healthy controls, but consistent with previous studies [2,3] this effect was 
greatly amplified in the PD group. We assume that these gait disturbances are specific to PD 
freezers since a previous study [3] found clear differences in the slowing phenomenon between 
the FOG and non-FOG groups. Slowing at doorways did not likely result from changes in the 
background stride lengths of the groups, since medications and STN-DBS significantly increased 
this but did not improve the slowing effect of doors (there were no door-width by treatment 
interactions). Rather, the observed slowing may result from a visuomotor process, where visually 
specified information about door width determines how much one must slow down to pass 
through the door accurately. The dramatic slowing of PD freezers is consistent with the 
hypothesis that visuomotor processing is different in these patients, specifically that they produce 
exaggerated responses to visual information [2]. This perspective may help explain the 
exaggerated responses of PD patients in other tasks [27-30]. An alternative explanation is that 
the doorway removes attention from walking, thus interfering with voluntary compensation for 
an underlying short stride length [31]. Neither medication nor STN-DBS alleviated door width-
related slowing. This is of course specific to our patient sample and should be tested across 
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different patient and surgical groups; however, the failure of medications to change door width-
related slowing replicates an earlier study with a different, non-implanted group [2]. Together 
these studies suggest that brain regions other than the basal ganglia may play a role in door-
provoked slowing. Interestingly, lateral premotor areas of cortex in PD patients have been 
reported to show excessive activation to visual information during walking [32] and may process 
visual information for walking as they do for reaching [33-35]. 
Freeze behaviour and its treatment 
We used two criteria to define objectively freeze-like events (FLEs). These agreed well with 
clinical ratings of freeze behaviour and provide objective measures comparable to inter-rater 
reliability (Supplementary material). Future studies should validate these measures in a larger 
cohort of patients. However, considering the data in this way removed the subjective element 
from defining freeze events, and provided measures which allow reliable, replicable 
identification of freezes, even those of short duration. These measures showed that freeze 
behaviour tends to occur near a doorway and with greater frequency as door width decreases. 
This confirms the observation that doorways elicit freeze behaviour in PD [1] and shows that the 
doorway isy are a powerful tool for experimentally manipulating freezing in a simple, 
naturalistic and replicable manner.  
Doorway-evoked freezingThis information can be used as an important complement to other 
recently described methods of evoking freezes in laboratory settings [4, 5, 6], and f. Future work 
may wish to compare these methods experimentally.  
A particularly influential theory of freezing is that it is caused by a reduction in baseline 
stridelength coupled to a sequence effect (progressive shortening of steps during walking) [6]. As 
discussed above our data are highly partially consistent with the relation betweenof slowing and 
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12
freezing – here we found that both were sensitive to door width. Indeed and the slowing 
produced by visuomotor dysfunction could in turn cause freezing through a sequence effect 
[6,36,37]. Indeed, closing eyes can help reduce freezing [38]. However, the differential effects of 
the two treatments suggest that other mechanisms may have contributed to freezing in the current 
study. That is, both treatments significantly improved baseline walking speed and door-width 
related slowing, whereas only medication reduced the risk of freezing (STN-DBS did not). while 
door-width related slowing was not significantly improved by either treatment, FLE risk was 
decreased by medication. This suggests that other mechanisms may have contributed to freezing 
in the current study. Furthermore baseline slowing was not a likely determinant of freezing, since 
it was significantly improved by both treatments whereas freezing was only reduced by 
medication.  The results are consistent with the suggestion that high stride time variability is 
associated with freezing [39] because, like freezing, it was improved by medication but not by 
STN-DBS. This discussion of how gait variables relate to freezing is based on the variation we 
naturally observed across different treatment conditions. In future work it would be ideal to also 
experimentally manipulate gait variables, for example by asking patients or healthy controls to 
walk at a different stride length. 
More work is therefore needed to develop theories of freezing which can account for the 
pattern of behaviour in the wide range of situations where it occurs. 
The lack of a STN-DBS effect on freezing is especially notable for several reasons. First, 
STN-DBS increased walking speed and stride length. Second, in the same session and trials, 
UPDRS scores were improved more by STN-DBS than by medication. STN-DBS also increased 
walking speed and stride length. Second, these other effects were significant even though the 
stimulator was only off for a relatively short period before testing. Third, the postoperative drug 
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13
doses were less than would have been given if the disease had progressed without surgery, yet, in 
contrast to STN-DBS, medication still reduced FLE risk though STN-DBS did not. Consistent 
with previous work [15], the relative weakness effect of stimulation STN-DBS as a therapeutic 
tool is therefore quite specific to freezing. Of course, this need not generalise to all PD patients.is 
only true for our particular group of patients, and treatment must be tailored to individuals. The 
effects of STN on post-operative freezing are best predicted by the pre-operative response to 
levodopa [15] and stimulation parameters must be carefully adjusted [14]. WHowever, while 
STN-DBS may effectively reduce freezing in some patients, the present study highlights its 
potential limitations and the need to continue exploring new treatments for this disabling 
symptom of PD. However, the assessment of treatments is not straightforward as Recent 
advances show that freezing is a highly sensitive and complex phenomenon with idiosyncratic 
properties [40]. Much  and more work is therefore needed to develop theories of freezing which 
can account for the pattern of behaviour in the wide range of situations where it occurs 
understand its neural bases. 
Summary 
The variable-width doorway paradigm coupled with reproducible measurements of freeze 
behaviour provides a new experimental approach for investigating freezing. Using this approach, 
we show that the risk of freezing is highly sensitive to door width. The differential effects of 
treatments in this setting suggest separable mechanisms for the patients’ basic slow walking 
speed, door width-related slowing, and door width-related freezing, and highlight the need to 
explore alternative treatments for severe freezing of gait. 
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FIGURE LEGENDS 
 
Figure 1 Freeze-like event (FLE) definition shown for one example patient. FLEs defined as 
(A) outliers in distribution of double support times for each participant within each condition (B) 
times where velocity falls <10% of mean value on no-door trials. 
 
Figure 2 Walking velocity. Pelvis midpoint velocity in direction of progression, as a function of 
position in space. Traces for single PD participant in off/off state. Data filtered at 1Hz, plotted 
for each door condition. Dashed lines show measurement region. 
 
Figure 3 Freezes. Total freeze / FLE trials observed per condition across all PD participants by 
(A) door (B) treatment condition. Effects of (C) door width (D) treatment condition on odds ratio 
(FLE risk). Mean and 95% confidence intervals shown. 
 
Figure 4 Perceptual and motor performance. Means and standard errors shown by group and 
treatment for (A) passability judgements (B) time to turn 360°. 
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